American Diabetes Association

Patients with diabetic retinopathy showed significantly higher updated first-year HbA1c and at follow-up compared to those free from DR.

A higher percentage of participants in the pooled dulaglutide group had a glycated hemoglobin level of <7.0% than the placebo group at week 26 of the AWARD-PEDS trial.

Data show the mean percentage change in weight at week 72 was -15.0% with 5-mg weekly doses of tirzepatide, -19.5% with 10-mg, and -20.9% with 15-mg dose, compared to -3.1% with placebo.

The late-breaking data show SGLT2is are underutilized in patients with heart failure with or without type 2 diabetes despite guideline recommendations.

The findings are in contrast to previous research that suggests an inverse relationship between moderate-to-vigorous physical activity and HbA1c, TIR.

The mean time below range following exercise sessions was significantly lower with IGlar U300 compared to IDEG at the 100% dose.

The late-breaking findings at ADA 2022 suggest patients were more often prescribed oral semaglutide by primary care physicians than endocrinologists.

Prof. Hertzel Gerstein discusses new ELIXA biomarker findings from ADA 2022.

However, the post-hoc analysis found a greater variability in HbA1c levels was associated with increased risk of cardiorenal outcomes.

The diabetologist and professor discusses new findings from the ReTUNE trial, which disparage the utility of BMI in defining diabetes risk and remission opportunity.

New post hoc data from the STEP 1 and 4 trials show an approximate 60% risk reduction of type 2 diabetes over 10 years versus placebo.

A greater reduction in UACR was observed with finerenone in patients taking GLP-1RA at baseline.

Dennis Bruemmer, MD discusses new agents and perspectives on care in treating patients with type 2 diabetes at high risk of CV, renal complications.

Investigators say that dietary habits in youth and young adult patients with diabetes can be impacted by income, employment, ethnicity, and a variety of other factors.

Elaine M. Apperson discusses treating diabetes in a pediatric population, including diabetes burnout, the effects of food deserts, and the consequences of COVID-19 on treatment.

Data show event rates varied two-fold across regions, with risk reduction of T2D and CKD events across geographic regions without heterogeneity.

Part 2 of a Q&A with Elena Christofides, MD highlighting important discussions surrounding ADA 2021, including semaglutide and obesity treatments as they relate to T2D.

Researchers push for transparency between health care professionals and patients with diabetes about the safety and efficacy of the influenza vaccine

In part 1 of a Q&A, Elena Christofides, MD highlights important discussions surrounding ADA 2021, including cardiometabolic medicine and risk factors for T1D.

Investigative ORMD-0701 has potential to regulate the insulin-glucagon balance in patients.

Changes in physical activity and diet may be main cause for worsening of diabetes control.

Data show similar family impact and distress scores at baseline and 3-months, highlighting continued impact of COVID-19 on T1D population.

A longer time spent in hypoglycemia over a 24-hour period was associated with disrupted sleep among children with type 1 diabetes.

Matthew Budoff, MD highlights his own preferred methods of treatment and what might need to be done to help doctors and patients through the process.

The study shows a reduction in hemoglobin and a reduced risk of hypoglycemia in participants.

Of the two diabetes treatments included in the study, patients with Gla-300 had lower recorded total health costs and greater commitment to treatment.

Data show a 38% reduction in T2D incidence with dapagliflozin compared to placebo in patients with CKD.

Data show 66% of healthcare professionals reported greater confidence in prescribing SGLT2i, while 55% reported greater confidence in prescribing GLP-1.

Researchers found a significant interaction between SGLT2 inhibitors based on age and eGFR.

Fluid regulation is important to the prevention of heart failure.